Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.63 | N/A | +14.75% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.63 | N/A | +14.75% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management expressed a focus on long-term growth through R&D. They did not provide specific guidance for future performance.
Management highlighted the importance of ongoing research and development.
They emphasized their commitment to innovation in the healthcare sector.
Gilead Sciences reported a better-than-expected EPS, indicating strong performance in that area. However, without revenue figures and stock reaction data, it's difficult to assess overall market sentiment. The lack of guidance may leave investors uncertain about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NETFLIX INC
Jan 26, 2009